Actinium Forms Nuclear Medicine Focused Advisory Board to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
270
Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning

NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.   (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that it has appointed the members of its Nuclear Medicine Clinical Advisory Board.  The following nuclear medicine physicians and scientists have joined the Company’s advisory board:

Member Medical Institution Affiliation
David Colcher, Ph.D. City of Hope
Johannes Czernin, M.D. UCLA
Ghassan El-Haddad, M.D. Moffitt Cancer Center
Dan Pryma, M.D. University of Pennsylvania
Franklin Wong, M.D., Ph.D., J.D. MD Anderson Cancer Center
Michael Yu, M.D. Fox Chase Cancer Center
   

Dr. Mark Berger, Actinium’s Chief Medical Officer said, “We are excited to have assembled such a strong advisory board of leading nuclear medicine physicians and scientists.  Having access to their input, which is driven by real world experience with our targeted conditioning and ARC drug candidates will be invaluable to our current and future development activities.  Based on the excellent contributions from our first meeting, I am confident that the board’s expertise and strategic guidance will position us for future success.”

Actinium is developing Antibody Radio-Conjugates (ARCs) that combine the targeting capabilities of monoclonal antibodies with the cell kill ability of radioisotopes.  Actinium’s most advanced ARC, Iomab-B, targets CD45 and is currently being studied in a pivotal Phase 3 trial for targeted conditioning prior to a bone marrow transplant, which is a potentially curative treatment option for patients with a number of hematologic diseases.  Actinium is also developing its CD33 program that is being studied in 5 Phase 1 and Phase 2 trial for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma, which all express CD33.  Recognizing the importance of the nuclear medicine community to its ARC drug candidates, Actinium has formed Nuclear Medicine Clinical Advisory Board in anticipation of continued clinical development expansion and potential commercialization of Iomab.

Sandesh Seth, Actinium’s Chairman and CEO said, “With Iomab-B progressing in its pivotal Phase 3 trial, our attention is turning to realizing our goal of improving access and outcomes to bone marrow transplant through targeted conditioning.  We have formed our nuclear medicine advisory boards to gain insights from physicians at key medical centers that treat a significant number of patients and are expected to be key commercial sites.  These advisory boards will augment our also world-class scientific and medical advisory boards that provide expert guidance specific to our Iomab-B and CD33 ARC programs.  We are excited to have assembled such esteemed physicians and scientists to our advisory boards and look forward to the contributions they will make to Actinium’s endeavor to be the leader in targeted conditioning.”

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells.  The Company’s targeted Antibody Radio-Conjugates (ARCs), combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes.  Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies.

Iomab-B, Actinium’s lead product candidate, is currently enrolling patients in a pivotal Phase 3 trial. Iomab-B combines the anti-CD45 monoclonal antibody BC8 labeled with iodine-131 and is designed to condition the bone marrow prior to a bone marrow transplant without the need for intense chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) of age 55 or older.  Actinium’s pipeline also includes a potentially best-in-class CD33 program with our ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225.  Its CD33 program is currently being studied in Phase 2 and Phase 1 clinical trials for patients with AML, myelodysplastic syndrome (MDS) and multiple myeloma. 

Actinium is also developing its proprietary Actinium Warhead Enabling (AWE) technology platform to utilize the highly differentiated radioisotope actinium-225 with a wide range of targets. AWE is being utilized in a collaborative research partnership with Astellas Pharma, Inc.

More information is available at www.actiniumpharma.com and our Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma .

Forward-Looking Statements for Actinium Pharmaceuticals, Inc. 

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update.  These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contact:

Actinium Pharmaceuticals, Inc. Steve O'Loughlin Principal Financial Officer soloughlin@actiniumpharma.com

Investor Relations Marek Ciszewski, J.D. 949.574.3860 ATNM@liolios.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 65

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 108

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 29

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 65

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 53

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 164

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 40

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 125

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 59

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading

Top 5 Most Recently Viewed Articles

Concentrix Unveils Ambitious Sustainability Goals for 2025

Updated Category News Views 366

Concentrix Releases Significant Sustainability Report Concentrix Corporation (NASDAQ: CNXC), a leader in global technology and services, recently revealed its 2025 Sustainability Report titled ‘The Power of One’. This comprehensive document showcases the company’s commitment to achieving its 2030 environmental, social, and governance (ESG) goals. These objectives...

Continue Reading
Hingham Institution for Savings Achieves Remarkable Q3 Growth

Updated Category News Views 193

Summary of Third Quarter Financial Results Hingham Institution for Savings (NASDAQ: HIFS) recently announced its financial results for the quarter ending September 30, 2025, reflecting a significant leap in profitability and growth metrics. The bank’s strategic approach and operational focus have led to these favorable outcomes. Earnings Overview The net income for the...

Continue Reading
Birchtech Corp. Announces Third Quarter Earnings Call Details

Updated Category News Views 149

Birchtech Corp. Announces Third Quarter Earnings Call Details Birchtech Corp. (TSX:BCHT) (OTCQB:BCHT) is making waves in the specialty activated carbon industry. As a recognized leader in technologies for sustainable air and water treatment, this Texas-based company is gearing up for its third-quarter earnings call, scheduled for 5:00 p.m. Eastern Time on a Thursday in...

Continue Reading
Syntec Optics Enhances Product Lines for Next Generation Markets

Updated Category News Views 251

Syntec Optics Promotes Growth in the Satellite Sector Syntec Optics Holdings, Inc. (Nasdaq: OPTX), based in Rochester, New York, is making significant strides in the expanding space market. The company is not just a leader in advanced technology, defense, biomedical, and communications equipment but is now pivoting towards a profound expansion of its space products...

Continue Reading
Laura Celeste Updegraff: Trailblazer in Military Leadership and HR

Updated Category News Views 248

Celebrating Leadership and Achievement Laura Celeste Updegraff, MBA, MS, stands out as a magnificent figure in leadership, recognized within The Inner Circle as a Pinnacle Professional Member Inner Circle of Excellence. Her remarkable journey highlights a deep commitment to service in the U.S. Army and a strong dedication to human resources leadership. A Distinguished...

Continue Reading